Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1998;43(3):311-9.
doi: 10.1007/BF02818617.

Pathogenic Neisseria--interplay between pro- and eukaryotic worlds

Affiliations
Review

Pathogenic Neisseria--interplay between pro- and eukaryotic worlds

T F Meyer. Folia Microbiol (Praha). 1998.

Abstract

The pathogenic Neisseria species constitute a multi-faceted infection model of a highly adapted pathogen-host relationship. Several bacterial and host-cell factors involved in the cellular cross-talk have been recently unraveled. Using Neisseria gonorrhoeae as a prototype, several structurally variable surface proteins, including pili and Opa proteins, have been revealed as adhesins recognizing distinct host-cell receptors. The Opa proteins, in particular, are important in facilitating interaction with heparan sulfate proteoglycan receptors and members of the CD66 and integrin receptor families. These interactions not only enable the pathogens' anchoring, and penetration into, the human mucosa but also stimulate cellular signaling cascades involving the phosphatidylcholine-dependent phospholipase C, acidic sphingomyelinase and protein kinase C in epithelial cells, and Src-related kinases, Rac1, p21-activated kinase and Jun N-terminal kinase in phagocytic cells. Activation of these pathways is essential for the entry and intracellular accommodation of the pathogens but also leads to an early induction of cytokine release, thus priming the immune response. It is believed that detailed knowledge of cellular signaling cascades activated by infection will aid us in applying known and novel interfering drugs, in addition to classical antibiotic therapy, to the therapeutic and prophylactic treatment of persistent or otherwise difficult-to-treat bacterial infections.

PubMed Disclaimer

Similar articles

Cited by

References

    1. EMBO J. 1995 May 15;14(10):2144-54 - PubMed
    1. Mol Microbiol. 1996 Mar;19(6):1357-72 - PubMed
    1. J Clin Lab Anal. 1991;5(5):344-66 - PubMed
    1. FEBS Lett. 1998 Mar 6;424(1-2):84-8 - PubMed
    1. Cell. 1986 Jan 17;44(1):107-15 - PubMed

LinkOut - more resources